Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Investing Activities: 2015-2025

Historic Cash from Investing Activities for Viking Therapeutics (VKTX) over the last 10 years, with Sep 2025 value amounting to $160.0 million.

  • Viking Therapeutics' Cash from Investing Activities rose 517.83% to $160.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.4 million, marking a year-over-year increase of 151.96%. This contributed to the annual value of -$553.4 million for FY2024, which is 208.99% down from last year.
  • Per Viking Therapeutics' latest filing, its Cash from Investing Activities stood at $160.0 million for Q3 2025, which was up 276.48% from $42.5 million recorded in Q2 2025.
  • Over the past 5 years, Viking Therapeutics' Cash from Investing Activities peaked at $160.0 million during Q3 2025, and registered a low of -$459.8 million during Q1 2024.
  • Moreover, its 3-year median value for Cash from Investing Activities was $6.6 million (2024), whereas its average is -$42.4 million.
  • Per our database at Business Quant, Viking Therapeutics' Cash from Investing Activities tumbled by 21,018.65% in 2024 and then soared by 517.83% in 2025.
  • Over the past 5 years, Viking Therapeutics' Cash from Investing Activities (Quarterly) stood at $27.4 million in 2021, then slumped by 73.51% to $7.3 million in 2022, then soared by 392.19% to $35.7 million in 2023, then crashed by 81.57% to $6.6 million in 2024, then spiked by 517.83% to $160.0 million in 2025.
  • Its Cash from Investing Activities was $160.0 million in Q3 2025, compared to $42.5 million in Q2 2025 and $63.2 million in Q1 2025.